News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
705,182 Results
Type
Article (41815)
Company Profile (330)
Press Release (663037)
Section
Business (210134)
Career Advice (2075)
Deals (36572)
Drug Delivery (96)
Drug Development (82799)
Employer Resources (171)
FDA (16478)
Job Trends (15357)
News (355396)
Policy (33819)
Tag
Academia (2574)
Alliances (51088)
Alzheimer's disease (1247)
Approvals (16409)
Artificial intelligence (140)
Bankruptcy (362)
Best Places to Work (11672)
Biotechnology (214)
Breast cancer (122)
Cancer (1110)
Cardiovascular disease (103)
Career advice (1737)
Cell therapy (238)
Clinical research (65789)
Collaboration (395)
Compensation (202)
COVID-19 (2601)
C-suite (96)
Data (1135)
Diabetes (154)
Diagnostics (6224)
Earnings (86508)
Employer resources (149)
Events (112340)
Executive appointments (318)
FDA (17026)
Funding (359)
Gene therapy (188)
GLP-1 (611)
Government (4445)
Healthcare (18851)
Infectious disease (2686)
Inflammatory bowel disease (110)
Interviews (319)
IPO (16580)
Job creations (4051)
Job search strategy (1487)
Layoffs (433)
Legal (8318)
Lung cancer (172)
Manufacturing (185)
Medical device (13259)
Medtech (13264)
Mergers & acquisitions (20065)
Metabolic disorders (420)
Neuroscience (1531)
NextGen Class of 2024 (6624)
Non-profit (4512)
Northern California (1489)
Obesity (242)
Opinion (203)
Patents (105)
People (58235)
Pharmaceutical (94)
Phase I (20346)
Phase II (28952)
Phase III (21718)
Pipeline (460)
Postmarket research (2644)
Preclinical (8679)
Radiopharmaceuticals (241)
Rare diseases (229)
Real estate (6240)
Regulatory (22368)
Research institute (2358)
Resumes & cover letters (358)
Southern California (1309)
Startups (3712)
United States (13674)
Vaccines (568)
Weight loss (183)
Date
Today (4)
Last 7 days (675)
Last 30 days (3631)
Last 365 days (36226)
2024 (33273)
2023 (40631)
2022 (51798)
2021 (56331)
2020 (54796)
2019 (47400)
2018 (35771)
2017 (33138)
2016 (32662)
2015 (38615)
2014 (32517)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (776)
Arizona (199)
Asia (39993)
Australia (6395)
California (3356)
Canada (1301)
China (257)
Colorado (150)
Connecticut (156)
Europe (85155)
Florida (462)
Georgia (116)
Illinois (348)
Indiana (204)
Kansas (96)
Maryland (581)
Massachusetts (2654)
Michigan (159)
Minnesota (274)
New Jersey (972)
New York (968)
North Carolina (721)
Northern California (1489)
Ohio (139)
Pennsylvania (852)
South America (1157)
Southern California (1309)
Texas (475)
Washington State (369)
705,182 Results for "chiesi pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Bio NC
Chiesi to Present New Data Showcasing Depth of Respiratory Leadership at the American Thoracic Society 2024 International Conference
Chiesi USA, Inc. (key-A-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), today announced the presentation of eight abstracts from Chiesi’s global respiratory research portfolio at the American Thoracic Society (ATS) 2024 International Conference in San Diego from May 17-22, 2024.
May 16, 2024
·
6 min read
Business
Chiesi USA Appoints Richard Smith as Vice President and Business Unit Leader, U.S. AIR
Chiesi USA, Inc. today announced it has appointed Richard Smith as vice president and business unit leader of U.S. AIR.
April 15, 2024
·
4 min read
Business
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
Gossamer Bio, Inc. and Chiesi Farmaceutici S.p.A announced that they have entered into a global collaboration and license agreement to develop and commercialize seralutinib.
May 6, 2024
·
9 min read
Genetown
Chiesi Global Rare Diseases Showcases Ongoing Commitment to Multiple Rare Diseases Communities at ENDO 2024 Meeting Debut
Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, announced updates from their rare endocrine disease portfolio with two late-breaking poster presentations and one oral presentation during the Endocrine Society’s ENDO 2024 Meeting that was held June 1-4, 2024, in Boston, Massachusetts.
June 14, 2024
·
9 min read
Press Releases
Chiesi Group’s new Biotech Center of Excellence brings the future of medicine to Parma, Italy
October 15, 2024
·
4 min read
Genetown
Chiesi Global Rare Diseases Makes Debut in the Endocrinology Landscape with Multiple Presentations at the Endocrine Society’s ENDO 2024 Meeting
Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced that three abstracts have been accepted for presentation at the Endocrine Society’s ENDO 2024 Meeting to be held June 1-4, 2024, in Boston, Massachusetts.
May 22, 2024
·
5 min read
Genetown
Chiesi Global Rare Diseases Announces Publication of Results from Fabry Disease Patient Survey
Chiesi Global Rare Diseases today announced the publication of results from a Fabry disease patient survey in the peer-reviewed Orphanet Journal of Rare Diseases.
April 24, 2024
·
4 min read
Press Releases
Chiesi Global Rare Diseases Announces Publication of Results from Phase 3 BRIGHT Study of ELFABRIO® (pegunigalsidase alfa-iwxj) in Fabry Disease
October 29, 2024
·
7 min read
Drug Development
Oak Hill Bio and Chiesi Group Announce First Patient Enrolled in the Resumed Phase 2b Clinical Study Evaluating OHB-607 for the Prevention of Bronchopulmonary Dysplasia, the Most Common Cause of Chronic Lung Disease in Premature Infants
Oak Hill Bio and Chiesi announced that the first patient has been enrolled in a resumed Phase 2b clinical study to assess the efficacy and safety of OHB-607, an investigational drug candidate being developed to treat complications of extremely premature birth, including bronchopulmonary dysplasia, a serious condition for which there are no approved therapies.
May 17, 2024
·
4 min read
Bio NC
Chiesi Group Mid-Year Financial Results Demonstrate Strong Growth for 2023
Chiesi USA, Inc., a Cary-based specialty pharmaceutical company, announced that Chiesi Group is continuing to experience major growth this year.
August 8, 2023
·
4 min read
1 of 70,519
Next
